Does the media favor IMVT or NRIX?

In the previous week, Nurix Therapeutics had 7 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for Immunovant. Nurix Therapeutics' average media sentiment score of 1.11 beat Immunovant's score of 0.79 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or RYTM?

In the previous week, Nurix Therapeutics had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Nurix Therapeutics and 4 mentions for Rhythm Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 1.11 beat Rhythm Pharmaceuticals' score of 0.53 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, LNTH or NRIX?

Lantheus has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.46 $233.56M $4.15 25.55 Nurix Therapeutics $71.78M 27.17 -$264.46M -$3.16 N/A

Is LNTH or NRIX more profitable?

Lantheus has a net margin of 18.05% compared to Nurix Therapeutics' net margin of -411.37%. Lantheus' return on equity of 29.32% beat Nurix Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Nurix Therapeutics -411.37% -64.21% -48.44%

Does the media prefer LNTH or NRIX?

In the previous week, Nurix Therapeutics had 5 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Nurix Therapeutics and 4 mentions for Lantheus. Nurix Therapeutics' average media sentiment score of 1.11 beat Lantheus' score of 0.46 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTCT or NRIX?

In the previous week, PTC Therapeutics had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 13 mentions for PTC Therapeutics and 9 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.11 beat PTC Therapeutics' score of 0.49 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or MIRM?

In the previous week, Nurix Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Nurix Therapeutics and 8 mentions for Mirum Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 1.11 beat Mirum Pharmaceuticals' score of 0.92 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nurix Therapeutics (NRIX) Competitors

$18.86 +0.21 (+1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$18.73 -0.13 (-0.68%)

As of 07:46 PM Eastern

Compare

NRIX vs. IMVT, RYTM, LNTH, PTCT, and MIRM

Should you buy Nurix Therapeutics stock or one of its competitors? MarketBeat compares Nurix Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nurix Therapeutics include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), PTC Therapeutics (PTCT), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Nurix Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Immunovant has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Nurix Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Nurix Therapeutics	$71.78M	27.17	-$264.46M	-$3.16	N/A

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

In the previous week, Nurix Therapeutics had 7 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for Immunovant. Nurix Therapeutics' average media sentiment score of 1.11 beat Immunovant's score of 0.79 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Immunovant presently has a consensus target price of $37.33, suggesting a potential downside of 0.76%. Nurix Therapeutics has a consensus target price of $32.20, suggesting a potential upside of 70.73%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Nurix Therapeutics beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Rhythm Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Nurix Therapeutics currently has a consensus target price of $32.20, suggesting a potential upside of 70.73%. Rhythm Pharmaceuticals has a consensus target price of $133.13, suggesting a potential upside of 25.36%. Given Nurix Therapeutics' higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$71.78M	27.17	-$264.46M	-$3.16	N/A
Rhythm Pharmaceuticals	$217.17M	33.51	-$196.54M	-$3.13	N/A

Nurix Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

In the previous week, Nurix Therapeutics had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Nurix Therapeutics and 4 mentions for Rhythm Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 1.11 beat Rhythm Pharmaceuticals' score of 0.53 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rhythm Pharmaceuticals beats Nurix Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Nurix Therapeutics had 5 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Nurix Therapeutics and 4 mentions for Lantheus. Nurix Therapeutics' average media sentiment score of 1.11 beat Lantheus' score of 0.46 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus target price of $101.86, indicating a potential downside of 3.94%. Nurix Therapeutics has a consensus target price of $32.20, indicating a potential upside of 70.73%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Nurix Therapeutics' net margin of -411.37%. Lantheus' return on equity of 29.32% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

Lantheus has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.46	$233.56M	$4.15	25.55
Nurix Therapeutics	$71.78M	27.17	-$264.46M	-$3.16	N/A

Summary

Lantheus and Nurix Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

PTC Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

In the previous week, PTC Therapeutics had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 13 mentions for PTC Therapeutics and 9 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.11 beat PTC Therapeutics' score of 0.49 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has higher revenue and earnings than Nurix Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.94	$682.64M	-$2.33	N/A
Nurix Therapeutics	$71.78M	27.17	-$264.46M	-$3.16	N/A

PTC Therapeutics has a net margin of -22.58% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Nurix Therapeutics	-411.37%	-64.21%	-48.44%

PTC Therapeutics presently has a consensus price target of $91.36, suggesting a potential upside of 11.23%. Nurix Therapeutics has a consensus price target of $32.20, suggesting a potential upside of 70.73%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Nurix Therapeutics beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Mirum Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Nurix Therapeutics has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

In the previous week, Nurix Therapeutics had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Nurix Therapeutics and 8 mentions for Mirum Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 1.11 beat Mirum Pharmaceuticals' score of 0.92 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics currently has a consensus price target of $32.20, suggesting a potential upside of 70.73%. Mirum Pharmaceuticals has a consensus price target of $139.80, suggesting a potential upside of 25.73%. Given Nurix Therapeutics' higher probable upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$71.78M	27.17	-$264.46M	-$3.16	N/A
Mirum Pharmaceuticals	$569.61M	11.90	-$23.36M	-$13.61	N/A

Mirum Pharmaceuticals has a net margin of -140.24% compared to Nurix Therapeutics' net margin of -411.37%. Mirum Pharmaceuticals' return on equity of -11.28% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Nurix Therapeutics beats Mirum Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.45B	$6.46B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-5.97	20.09	24.71	24.00
Price / Sales	27.17	188.30	492.47	90.40
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	3.57	8.28	10.82	6.53
Net Income	-$264.46M	$23.85M	$3.56B	$336.99M
7 Day Performance	10.49%	5.21%	1.67%	-0.22%
1 Month Performance	7.77%	2.19%	0.43%	0.77%
1 Year Performance	57.43%	60.99%	32.84%	31.57%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	3.3363 of 5 stars	$18.86 +1.1%	$32.20 +70.7%	+62.3%	$1.95B	$71.78M	N/A	300	Positive News
IMVT Immunovant	1.7729 of 5 stars	$38.10 +7.8%	$37.33 -2.0%	+141.1%	$7.26B	N/A	N/A	120
RYTM Rhythm Pharmaceuticals	2.9059 of 5 stars	$101.39 +4.8%	$133.13 +31.3%	+63.6%	$6.95B	$217.17M	N/A	140
LNTH Lantheus	2.9354 of 5 stars	$106.20 +2.3%	$101.86 -4.1%	+34.1%	$6.76B	$1.55B	25.59	1,193
PTCT PTC Therapeutics	2.5139 of 5 stars	$80.96 +2.5%	$91.36 +12.8%	+61.3%	$6.55B	$1.73B	N/A	1,410	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. IMVT, RYTM, LNTH, PTCT, and MIRM

How does Nurix Therapeutics compare to Immunovant?

Summary

How does Nurix Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Nurix Therapeutics compare to Lantheus?

Summary

How does Nurix Therapeutics compare to PTC Therapeutics?

Summary

How does Nurix Therapeutics compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. IMVT, RYTM, LNTH, PTCT, and MIRM

How does Nurix Therapeutics compare to Immunovant?

Is IMVT or NRIX more profitable?

Which has higher earnings & valuation, IMVT or NRIX?

Which has more volatility and risk, IMVT or NRIX?

Does the media favor IMVT or NRIX?

Do institutionals and insiders hold more shares of IMVT or NRIX?

Do analysts recommend IMVT or NRIX?

Summary

How does Nurix Therapeutics compare to Rhythm Pharmaceuticals?

Is NRIX or RYTM more profitable?

Do analysts rate NRIX or RYTM?

Which has better valuation & earnings, NRIX or RYTM?

Which has more risk & volatility, NRIX or RYTM?

Does the media favor NRIX or RYTM?

Summary

How does Nurix Therapeutics compare to Lantheus?

Does the media prefer LNTH or NRIX?

Do analysts prefer LNTH or NRIX?

Which has more volatility & risk, LNTH or NRIX?

Do insiders & institutionals have more ownership in LNTH or NRIX?

Is LNTH or NRIX more profitable?

Which has better earnings & valuation, LNTH or NRIX?

Summary

How does Nurix Therapeutics compare to PTC Therapeutics?

Which has more risk & volatility, PTCT or NRIX?

Does the media favor PTCT or NRIX?

Which has preferable earnings and valuation, PTCT or NRIX?

Is PTCT or NRIX more profitable?

Do analysts recommend PTCT or NRIX?

Summary

How does Nurix Therapeutics compare to Mirum Pharmaceuticals?

Which has more risk and volatility, NRIX or MIRM?

Does the media favor NRIX or MIRM?

Do analysts rate NRIX or MIRM?

Which has better valuation & earnings, NRIX or MIRM?

Is NRIX or MIRM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools